COURTNEY WUSS: Open Payments
NPI 1326593286 · LAKEWOOD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,591 in 97 payments from 13 companies in 2025. Trend: 2023 $5,069 · 2024 $2,297 · 2025 $1,591
Food & beverage: $1,591
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 25 | $485 |
| ABBVIE INC. | 20 | $265 |
| Teva Pharmaceuticals USA, Inc. | 20 | $192 |
| Otsuka America Pharmaceutical, Inc. | 12 | $156 |
| Madrigal Pharmaceuticals | 1 | $142 |
| Neurocrine BioSciences, Inc. | 5 | $107 |
| Alkermes, Inc. | 5 | $88 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Braeburn Inc. | 2 | $33 |
| Almatica Pharma LLC | 2 | $31 |
Products named: CAPLYTA, VRAYLAR, AUSTEDO XR, REZDIFFRA, REXULTI, INGREZZA, ARISTADA, Auvelity.
Industry payments across NJ — which companies pay providers there.
